Avoro Capital Advisors LLC — 13F Holdings & Portfolio
CIK 1633313 · latest 13F-HR filed 2026-08-14
Avoro Capital Advisors LLC manages $11.14B in 13F-reported U.S. long-equity assets across 26 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are UTHR (13.52%), ASND (12.24%), KRYS (9.64%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 7; 16 existing positions rose in reported value and 2 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 79.5%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 5, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AGHAZADEH, BEHZAD Control | MANAGING DIRECTOR since Sep 2017 | Less than 5% | Individual |
| AVORO CAPITAL L.P. Control | DIRECT OWNER since May 2019 | 75% or more | Domestic Entity |
| CAMMAROSANO, NEIL Control | CHIEF FINANCIAL OFFICER since May 2024 | Less than 5% | Individual |
| EPSTEIN, SCOTT, ANDREW Control | CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER since Jun 2014 | Less than 5% | Individual |
| AGHAZADEH, BEHZAD Control Indirect owner via AVORO CAPITAL L.P. | LIMITED PARTNER since May 2019 | 50–75% | Individual |
| AGHAZADEH, BEHZAD Control Indirect owner via AVORO CAPITAL GP LLC | MEMBER since May 2019 | 50–75% | Individual |
| AVORO CAPITAL GP LLC Control Indirect owner via AVORO CAPITAL L.P. | GENERAL PARTNER since May 2019 | General partner, trustee or manager | Domestic Entity |
| KONG, GARHENG, ALBERT Indirect owner via AVORO CAPITAL GP LLC | MEMBER since May 2019 | 50–75% | Individual |
Ownership & leadership changes · 8 filings with changes since Feb 22, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedCAMMAROSANO, NEIL · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ChangedEPSTEIN, SCOTT, ANDREW · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
- No longer listedAGHAZADEH, BEHZAD · LIMITED PARTNER · 75% or more · indirect via VENBIO SELECT ADVISOR L.P. · control person · listed since Sep 2017
- No longer listedAGHAZADEH, BEHZAD · MEMBER · 75% or more · indirect via VENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · control person · listed since Sep 2017
- No longer listedVENBIO SELECT ADVISOR L.P. · DIRECT OWNER · 75% or more · control person · listed since Sep 2017
- No longer listedVENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO SELECT ADVISOR L.P. · control person · listed since Sep 2017
- AddedAGHAZADEH, BEHZAD · LIMITED PARTNER · 50–75% · indirect via AVORO CAPITAL L.P. · control person
- AddedAGHAZADEH, BEHZAD · MEMBER · 50–75% · indirect via AVORO CAPITAL GP LLC · control person
- AddedAVORO CAPITAL GP LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via AVORO CAPITAL L.P. · control person
- AddedAVORO CAPITAL L.P. · DIRECT OWNER · 75% or more · control person
- AddedKONG, GARHENG, ALBERT · MEMBER · 50–75% · indirect via AVORO CAPITAL GP LLC
- No longer listedADELMAN, ROBERT · MANAGER · 25–50% · control person · listed since Jan 2013
- No longer listedGOODMAN, COREY, S. · MANAGER · 25–50% · control person · listed since Jan 2013
- AddedAGHAZADEH, BEHZAD · LIMITED PARTNER · 75% or more · indirect via VENBIO SELECT ADVISOR L.P. · control person
- AddedAGHAZADEH, BEHZAD · MEMBER · 75% or more · indirect via VENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · control person
- AddedVENBIO SELECT ADVISOR L.P. · DIRECT OWNER · 75% or more · control person
- AddedVENBIO SELECT ADVISOR MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO SELECT ADVISOR L.P. · control person
- ChangedAGHAZADEH, BEHZAD · title PORTFOLIO MANAGER → MANAGING DIRECTOR
- No longer listedBROOKE, PAUL, ALAN · MANAGER · 25–50% · control person · listed since Jan 2013
- ChangedADELMAN, ROBERT · now a control person
- AddedAGHAZADEH, BEHZAD · PORTFOLIO MANAGER · Less than 5% · control person
- AddedEPSTEIN, SCOTT, ANDREW · CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedADELMAN, ROBERT · title MANAGER AND CCO → MANAGER
- No longer listedVONEMSTER, KONRAD, HANS · MANAGER · 25–50% · control person · listed since Sep 2009
- AddedBROOKE, PAUL, ALAN · MANAGER · 25–50% · control person
- AddedGOODMAN, COREY, S. · MANAGER · 25–50% · control person
- ChangedADELMAN, ROBERT · title CHIEF COMPLIANCE OFFICER → MANAGER AND CCO; ownership Less than 5% → 25–50%
- ChangedVONEMSTER, KONRAD, HANS · title MANAGING MEMBER → MANAGER; ownership 75% or more → 25–50%
- AddedADELMAN, ROBERT · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedVONEMSTER, KONRAD, HANS · title MANAGING MEMBER/CHIEF COMPLIANCE OFFICER → MANAGING MEMBER
- ListedVONEMSTER, KONRAD, HANS · MANAGING MEMBER/CHIEF COMPLIANCE OFFICER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- KRYSTAL BIOTECH INC$327.5M +43.9%
- ARROWHEAD PHARMACEUTICALS INC$254.7M +38.0%
- DEFINIUM THERAPEUTICS INC$243.7M +257.8%
- KYMERA THERAPEUTICS INC$234.6M +37.7%
- UNIQURE NV$212.4M +218.0%
New Positions
- ASCENDIS PHARMA$1.36B
- HEMAB THERAPEUTICS HLDGS INC$70.7M
- FAETH THERAPEUTICS INC$36.1M
Exited Positions
- ASCENDIS PHARMA$1.16B
- APELLIS PHARMACEUTICALS INC$491.7M
- CENTESSA PHARMACEUTICALS PLC$454.0M
- TERNS PHARMACEUTICALS INC$300.2M
- SOLENO THERAPEUTICS INC$77.0M
Avoro Capital Advisors LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | UNITED THERAPEUTICS CORP | UTHR | 91307C102 | $1.51B | 13.52% | 2,777,777 | SH |
| 2 | ASCENDIS PHARMA | ASND | K08588103 | $1.36B | 12.24% | 5,111,111 | SH |
| 3 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $1.07B | 9.64% | 2,888,888 | SH |
| 4 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $984.4M | 8.84% | 1,833,333 | SH |
| 5 | ARGENX SE | ARGX | 04016X101 | $927.8M | 8.33% | 1,000,000 | SH |
| 6 | ARROWHEAD PHARMACEUTICALS INC | ARWR | 04280A100 | $925.6M | 8.31% | 11,355,555 | SH |
| 7 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $857.1M | 7.70% | 7,474,747 | SH |
| 8 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $430.2M | 3.86% | 2,297,000 | SH |
| 9 | CYTOKINETICS INC | CYTK | 23282W605 | $425.9M | 3.82% | 4,999,999 | SH |
| 10 | CELCUITY INC | CELC | 15102K100 | $355.7M | 3.19% | 3,400,000 | SH |
| 11 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $351.8M | 3.16% | 6,555,555 | SH |
| 12 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $348.7M | 3.13% | 5,777,777 | SH |
| 13 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $338.2M | 3.04% | 7,188,888 | SH |
| 14 | UNIQURE NV | QURE | N90064101 | $309.9M | 2.78% | 6,727,777 | SH |
| 15 | VERA THERAPEUTICS INC | VERA | 92337R101 | $245.6M | 2.21% | 5,723,888 | SH |
| 16 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $162.7M | 1.46% | 23,888,888 | SH |
| 17 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $123.1M | 1.11% | 12,540,000 | SH |
| 18 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $98.4M | 0.88% | 3,783,000 | SH |
| 19 | HEMAB THERAPEUTICS HLDGS INC | COAG | 423494103 | $70.7M | 0.63% | 1,925,150 | SH |
| 20 | GH RESEARCH PLC | GHRS | G3855L106 | $48.4M | 0.43% | 1,800,000 | SH |
| 21 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $45.9M | 0.41% | 2,500,000 | SH |
| 22 | SEPTERNA INC | SEPN | 81734D104 | $44.8M | 0.40% | 1,337,500 | SH |
| 23 | AVALO THERAPEUTICS | AVTX | 05338F306 | $43.1M | 0.39% | 2,333,333 | SH |
| 24 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $36.1M | 0.32% | 1,444,039 | SH |
| 25 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $13.1M | 0.12% | 2,849,402 | SH |
| 26 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $6.9M | 0.06% | 1,489,189 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $11.14B | 26 | 0001104659-26-096427 |
| 2026-03-31 | 2026-05-15 | $10.16B | 33 | 0001104659-26-061754 |
| 2025-12-31 | 2026-03-16 | $10.17B | 34 | 0001104659-26-027799 |
| 2025-12-31 | 2026-02-17 | $10.17B | 34 | 0001104659-26-015748 |
SUITE 800
NEW YORK, NY 10012